NCT04849910 - Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

May 28, 2025

Study Completion Date

May 28, 2025

Conditions

Leukemia, Myeloid, AcuteMyelodysplastic Syndromes

Interventions

BIOLOGICAL

VOR33

Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein

DRUG

Mylotarg

Infusion of Mylotarg

Trial Locations (15)

10032

Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

20892

National Institutes of Health, Clinical Center, Bethesda

30322

Winship Cancer Institute Emory University, Atlanta

33176

Miami Cancer Institute, Miami

44106

University Hospitals Seidman Cancer Center, Cleveland

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

63110

Washington University School of Medicine Siteman Cancer Center, St Louis

66205

The University of Kansas Cancer Center, Fairway

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

92037

University of California San Diego Moores Cancer Center, La Jolla

94305

Stanford Cancer Institute, Stanford

98109

Fred Hutchinson Cancer Research Center, Seattle

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

H1T2M4

Hôpital Maisonneuve-Rosemont, Montreal